Trials evaluating therapy escalation in interim PET-positive patients
| Trial . | N . | Clinical stage . | Median age (range), y . | Initial therapy . | Escalated therapy for PET+ patients . | CMR definition . | % PET+ . | Median follow-up, mo . | PFS for PET+ patients, % (y) . | OS for PET+ patients, % (y) . | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| US Intergroup S081621,22 | 358 | III-IV | 32 (18-60) | ABVD ×2 | EB ×6 | DS 1-3 | 22 | 45 | 64 (2) | 98 (2) | |
| United Kingdom RATHL23 | 1214 | IIB-IV or IIA unfavorable | 32 (18-79) | ABVD ×2 | EB ×3 or | DS 1-3 | 16 | 41 | 68 (3) | 86 (3) | |
| BEACOPP-14 ×4 | |||||||||||
| HD 060724 | 782 | IIB-IV | 31 (14-60) | ABVD ×2 | EB ×4 + BEACOPP ×4 ± rituximab | DS 1-3 | 19 | 43 | 60 (3) | 89 (3) | |
| GHSG HD1825 | 2101 | IIB-IV | 31 (23-44) | EB ×2 | EB ×6 + rituximab | DS 1-2 | 48 | 66 | 88.1 (5) | 93.9 (5) | |
| Control group: EB ×6 | 89.7 (5) | 96.4 (5) | |||||||||
| HD 080126 | 519 | IIB-IV | 33 (18-68) | ABVD ×2 | IGEV ×4 + ASCT | DS 1-2 | 20 | 27 | 76 (2) | 97 (2) | |
| Israeli H227 | 185 | IIB-IV, IPS 0-2 | 30 (18-60) | ABVD ×2 | EB ×4 | DS 1-3 | 12 | 55 | 68 (5) | 91 (5) |
| Trial . | N . | Clinical stage . | Median age (range), y . | Initial therapy . | Escalated therapy for PET+ patients . | CMR definition . | % PET+ . | Median follow-up, mo . | PFS for PET+ patients, % (y) . | OS for PET+ patients, % (y) . | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| US Intergroup S081621,22 | 358 | III-IV | 32 (18-60) | ABVD ×2 | EB ×6 | DS 1-3 | 22 | 45 | 64 (2) | 98 (2) | |
| United Kingdom RATHL23 | 1214 | IIB-IV or IIA unfavorable | 32 (18-79) | ABVD ×2 | EB ×3 or | DS 1-3 | 16 | 41 | 68 (3) | 86 (3) | |
| BEACOPP-14 ×4 | |||||||||||
| HD 060724 | 782 | IIB-IV | 31 (14-60) | ABVD ×2 | EB ×4 + BEACOPP ×4 ± rituximab | DS 1-3 | 19 | 43 | 60 (3) | 89 (3) | |
| GHSG HD1825 | 2101 | IIB-IV | 31 (23-44) | EB ×2 | EB ×6 + rituximab | DS 1-2 | 48 | 66 | 88.1 (5) | 93.9 (5) | |
| Control group: EB ×6 | 89.7 (5) | 96.4 (5) | |||||||||
| HD 080126 | 519 | IIB-IV | 33 (18-68) | ABVD ×2 | IGEV ×4 + ASCT | DS 1-2 | 20 | 27 | 76 (2) | 97 (2) | |
| Israeli H227 | 185 | IIB-IV, IPS 0-2 | 30 (18-60) | ABVD ×2 | EB ×4 | DS 1-3 | 12 | 55 | 68 (5) | 91 (5) |
ASCT, autologous stem cell transplantation; BEACOPP, bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone; BEACOPP-14, BEACOPP administered in 14-day cycles; CMR, complete metabolic response; DS, Deauville score; EB, escBEACOPP; IGEV, ifosfamide, gemcitabine, and vinorelbine; N, number of patients; RATHL, Risk-Adapted Therapy in Hodgkin Lymphoma.